Oncolytics Biotech® Inc.'s REOLYSIN® More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer Apr 5, 2017 07:00AM
Oncolytics Biotech® Inc.'s REOLYSIN® Provides Statistically Significant Improvement in Overall Survival in Canadian Cancer Trials Group Sponsored Randomized Phase 2 Study in Metastatic Breast C Mar 31, 2017 04:23PM
Oncolytics Biotech® Inc. Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting Mar 2, 2017 06:30AM